Early stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years, and the doses were found to be well tolerated
from Latest News https://ift.tt/3sh7FNm
Friday, 13 August 2021
Bharat Biotech's nasal Covid-19 vaccine advances into next stage of trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment